In today’s briefing:
- ADARx Pharmaceuticals (ADRX): Bio IPO Opens 30% Higher, but Selling Pressure Builds Into the Close
- Wockhardt: Zaynich Launch Unlocks a Multi-Market Anti-Infective Franchise
ADARx Pharmaceuticals (ADRX): Bio IPO Opens 30% Higher, but Selling Pressure Builds Into the Close
- ADARx upsized its IPO to 26.3 million shares at $17.00, the high end of the range, opening at $22.10 for a 30% gain.
- The offering was 10 times oversubscribed, with the top 25 accounts receiving 95% of shares and nearly 100 accounts receiving zero allocation.
- Shares closed at $19.35 after reaching $23.21, highlighting persistent selling pressure despite strong demand and a constructive biotech IPO outcome.
Wockhardt: Zaynich Launch Unlocks a Multi-Market Anti-Infective Franchise
- US FDA approved Zaynich (cefepime-zidebactam) on 29–30 May 2026 for adult complicated UTI, days after DCGI clearance on 27 May. An EMA file is already under Accelerated Assessment.
- This is the first fully Indian-discovered new chemical entity to win FDA approval. Management points to $1.5–2 billion peak sales against a $7–9 billion resistant Gram-negative opportunity.
- Insulin share gains from Novo Nordisk’s disposable-pen exit, Emrok’s India franchise and a 0.10 net-debt-to-equity book give Wockhardt the cash and channels to commercialise without rushed dilution.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
